Latest News for SLXN
Silexion Therapeutics Corp (NASDAQ: SLXN - Get Free Report) was down 0.9% during mid-day trading on Thursday. The stock traded as low as $1.09 and last traded at $1.11. Approximately 101,379 shares traded hands during mid-day trading, an increase of 36% from the average daily volume of 74,338 shares. The stock had previously closed at
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLXN.
U.S. House Trading
No House trades found for SLXN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.